Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial
The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a manageable safety profile.
